Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Sara Garcia-Gomes

Nurse Practitioner, Family Putnam, CT Nurse Practitioner

NPI 1467061655 CMS profile 10852464

353 Pomfret St, Putnam, CT 06260

Open in the dashboard

General payments

$18,727

920 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sara Garcia-Gomes of Putnam, CT is reported in the CMS Open Payments database as having received $18,727 across 920 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,175 190
2024 General $4,248 192
2023 General $3,312 175
2022 General $3,263 172
2021 General $3,728 191

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sara Garcia-Gomes
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Sara Garcia-Gomes were reported at $4,175. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Sara Garcia-Gomes Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $3,728 $124 $35–$379 $132
2022 $3,263 $141 $44–$430 $149
2023 $3,312 $154 $49–$476 $160
2024 $4,248 $165 $51–$504 $164
2025 $4,175 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $2,010 121 payments
  2. AstraZeneca Pharmaceuticals LP $1,940 77 payments
  3. ITI, Inc. $1,096 56 payments
  4. Janssen Pharmaceuticals, Inc $951 43 payments
  5. Teva Pharmaceuticals USA, Inc. $879 41 payments
  6. Novo Nordisk Inc $840 46 payments
  7. Pfizer Inc. $725 42 payments
  8. Amgen Inc. $660 31 payments
  9. Lilly USA, LLC $610 21 payments
  10. Alkermes, Inc. $560 29 payments
  11. Other $8,455 413 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $18,634 910 payments
  2. Education $93 10 payments
Products named General payments · program years 2021–2025
  1. TEZSPIRE $706 26 payments
  2. RYBELSUS $702 38 payments
  3. NURTEC ODT $679 39 payments
  4. CAPLYTA $664 40 payments
  5. SPRAVATO $643 25 payments
  6. Ozempic $640 37 payments
  7. UBRELVY $634 23 payments
  8. Korlym $552 24 payments
  9. VRAYLAR $533 49 payments
  10. QULIPTA $513 26 payments
  11. Other $17,565 873 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

920 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Connecticut

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record